Unicycive Therapeutics (UNCY) – Research Analysts’ Weekly Ratings Updates

Unicycive Therapeutics (NASDAQ: UNCY) has recently received a number of price target changes and ratings updates:

• 8/20/2026 – Unicycive Therapeutics had its “speculative buy” rating reaffirmed by Benchmark Co.. They now have a $15.00 price target on the stock, up from $13.00.
• 8/19/2026 – Unicycive Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/15/2026 – Unicycive Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/13/2026 – Unicycive Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $25.00 price target on the stock, down from $37.00.
• 8/12/2026 – Unicycive Therapeutics had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $20.00 price target on the stock, down from $22.00.
• 7/21/2026 – Unicycive Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/1/2026 – Unicycive Therapeutics had its price target lowered by Benchmark Co. from $18.00 to $13.00. They now have a “speculative buy” rating on the stock.
• 6/30/2026 – Unicycive Therapeutics had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $22.00 price target on the stock.
• 6/30/2026 – Unicycive Therapeutics had its price target lowered by HC Wainwright from $22.00 to $15.00. They now have a “buy” rating on the stock.
• 6/27/2026 – Unicycive Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.